World cdx 2024

BOSTON and ROLLE, Switzerland, Sept. 5, | PRNewswire —SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in to develop and deploy Boundless Bio's extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to identify patients with ecDNA amplified tumors using the SOPHiA DDM™ Platform. The two companies collaborated with precision medicine clinical research organization (CRO) Precision for Medicine, which contributes its state-of-the-art, CAP-accredited, CLIA-certified laboratory services to Boundless Bio's POTENTIATE Phase 1/2 clinical trial by successfully validating a proprietary workflow to process patient samples.

It is well established that oncogenic alterations, such as mutations and fusions, can lead to malignant cellular growth that results in cancer. While approved targeted agents are available to treat several types of oncogenic mutations, patients whose cancers harbor oncogene amplification typically do not derive the same benefit. O


Driving Drug-CDx Partnerships for Scalable Precision Medicine Access



With rising demand for targeted therapies and testing access, the Asia-Pacific region is becoming a rising player in the co-development and commercialization of drug-diagnostic strategies. In under a year, Singapore has accelerated public-private partnerships to scale genomic testing, China has expanded national reimbursement for liquid biopsies, and Japan has refined its regulatory framework for companion diagnostic approvals.  

Returning for its second year, the
World Liquid Biopsy & Companion Diagnostics Summit APAC
will unite + leaders across biopharma, diagnostics, regulation, and healthcare to drive the co-development and commercialization of affordable, scalable, and timely testing solutions.

Spanning oncology to neurology, chronic and rare diseases, join this APAC-dedicated forum addressing the full drug-diagnostic co-development journey, where precision partnerships are formed, regional strategies aligned, and precision medicine innovation accelerated for improved patient access across the region.




14th Annual World Clinical Biomarkers and Companion Diagnostics Summit


Since , we’ve led the way in spatial biology, being among the first to utilize machine learning and AI for spatial analysis and establishing ourselves as the most dependable partner for your clinical program. With seventeen US patents backing our proprietary image analysis technology, Flagship partners with you to deliver customized data to meet your unique needs. Starting with assessment and determining the correct modalities, our dedicated and collaborative scientific and project management teams provide end-to-end support throughout the entire process, from pre-IND to commercialization.


AI-powered digital pathology solutions

Biomarker development and validation

Spatial biology and molecular diagnostics analysis

Clinical trial support

CDx development

Regulatory guidance



Interested in partnering with us? Meet with us

 to discuss how our spatial biology solutions can accelerate your research or drug development program.






World Companion Diagnostics & Liquid Biopsy Summit APAC



In the last 12 months, precision healthcare in the Asia-Pacific region has seen a surge in technology advancements, including NGS and laboratory developed tests, approvals such as a companion diagnostic test for lung cancer, and evolving regulations throughout the region.

The
World Companion Diagnostics & Liquid Biopsy Summit APAC
has been put together to provide a dedicated forum for key stakeholders from biopharma, diagnostic providers and leading academics to overcome critical challenges in liquid biopsy and companion diagnostic (CDx) testing.



Where:
Conrad Centennial, Singapore


When:
November ,


Who:
+ precision medicine experts from across the APAC region and wider globe


Download the event agenda here:

This unique and important forum is uniting experts from
Singapore
,
Australia
,
China
,
Japan
,
Taiwan
,
the USA
and more to create a comprehensive framework for
successful drug-companion diagnostic co-development
and
robust biomarker testing
to accelerate patient access to personalized healthcare for improved outcomes in the APAC market.

This conference is *FREE